Ghosh A K, Smith N K, Prendiville J, Thatcher N, Crowther D, Stern P L
Cancer Research Campaign Department of Immunology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, United Kingdom.
Eur Cytokine Netw. 1993 May-Jun;4(3):205-11.
The effects of recombinant human interleukin-4 (rhu IL-4) on immunological parameters in patients receiving increasing doses of IL-4 in a Phase I trial were investigated. Peripheral blood mononuclear cells were phenotyped for a variety of lymphocyte markers, but no consistent effects were observed. However, increases in HLA Class II expression on monocytes were detected in four patients. NK and LAK activity were neither induced nor augmented by IL-4 treatment. Slight increases in proliferative responses to mitogens and cytokines were observed in some patients. The latter observations and other clinical studies suggest that a combination of IL-4 with IL-2 may be more effective in Phase II clinical trials.
在一项I期试验中，研究了重组人白细胞介素-4（rhu IL-4）对接受递增剂量IL-4治疗的患者免疫参数的影响。对外周血单个核细胞进行了多种淋巴细胞标志物的表型分析，但未观察到一致的效果。然而，在4名患者中检测到单核细胞上HLA II类表达增加。IL-4治疗既未诱导也未增强NK和LAK活性。在一些患者中观察到对有丝分裂原和细胞因子的增殖反应略有增加。后一项观察结果和其他临床研究表明，在II期临床试验中，IL-4与IL-2联合使用可能更有效。
